Stage IV Non-Small Cell Lung Cancer without Driver Alterations
Key Points
Key Points
This clinical practice guideline update addresses two overarching clinical questions:
- What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
- What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?
Treatment
...eatment...
...recommendations with multiple treatment op...
...al Question 1: What are the most e...
...Squamous Cell Carcinoma (No...
Patients with programmed death-liga...
...or patients with a programmed death-liga...
...For patients with a programmed death...
...ts with a programmed death-ligand 1 or...
1.4. For patients with a programme...
...tients with a programmed death-ligand...
...tients with a programmed death-ligand 1 or program...
...ents with PD-L1 expression TPS,...
...ents with PD-L1 expression TPS, 1–49%, clinic...
1.8. For patients with PD-L1 expressi...
...9. For patients with PD-L1 expression T...
...atients with PD-L1 expression TPS, 1–49%, cli...
...patients with PD-L1 expression TPS, 1–49%,...
...tients who are ineligible for or decline the combi...
...ts with unknown or negative PD-L1 ex...
....3. For patients with unknown or negati...
...nts with unknown or negative PD-L1 expre...
...tients with unknown or negative PD-L1 expression...
...6. For patients with unknown or negative PD-...
...For patients with unknown or negative PD-...
...mous Cell Carcinoma (SCC...
...with PD-L1 expression, TPS ≥50%:
.... For patients with PD-L1 expression,...
...r patients with PD-L1 expression,...
....3. For patients with PD-L1 expression, TPS ≥50%...
...4. For patients with PD-L1 expression...
...s with PD-L1 expression, TPS ≥50%,...
...ts with PD-L1 expression TPS, 1–49%:...
...or patients with PD-L1 expression TPS, 1â€...
...ts with PD-L1 expression TPS, 1–49%, clini...
...r patients with PD-L1 expression TPS, 1–49%, cli...
...patients with PD-L1 expression TPS, 1...
.... For patients with PD-L1 expression TPS, 1–49%...
...known or negative PD-L1 expression, TPS...
...or patients with unknown or negative PD-L1 expre...
....2. For patients with unknown or negative P...
.... For patients with unknown or nega...
...ents with unknown or negative PD-L1 expression, T...
...nts with Unspecified Histolog...
4.5. For patients with unknown or ne...
...s with unknown or negative PD-L1 expr...
...s with unknown or negative PD-L1 expression, TPS...
...vacizumab should be avoided for patients with s...
...tients with contraindications to bevacizuma...
...ts with Unspecified Histol...
.... Bevacizumab should be avoided for...
....9. Maintenance bevacizumab given wit...
...al Question 2: What are the most e...
...eviously treated with immune checkpoint therap...
...atients previously treated with immune checkpoint...
...sly treated with chemotherapy and immune...
...ents previously treated with chemotherapy and immu...
...patients previously treated with chemotherapy an...
...re 1. Second-Line and Subsequent Tre...
...gure 2. First-Line Treatment Options for Patie...
.... First-Line Treatment Options for Patient...